Latest news with #AcuityMD
Business Wire
28-04-2025
- Business
- Business Wire
AcuityMD Expands Care Journeys Solution with Enhanced Physician Referral Networks to Increase Patient Access to MedTech Innovations
BOSTON--(BUSINESS WIRE)-- AcuityMD, the MedTech Intelligence Platform, today announced a new solution that will help MedTech companies and healthcare providers (HCPs) deliver new treatment options to more patients. Referral Pathways in AcuityMD Care Journeys provides comprehensive patient referral data so MedTech commercial teams can easily identify the physicians who can most benefit from their products and bring innovations to more patients. Referral Pathways in AcuityMD Care Journeys provides comprehensive patient referral data so MedTech commercial teams can easily identify the physicians who can most benefit from their products and bring innovations to more patients Share AcuityMD Care Journeys, launched in October 2024, was designed to help MedTech companies demonstrate the improved clinical and financial outcomes their technology delivers for patients with complex diagnoses and treatment journeys – helping them drive product adoption with hospitals and physicians. Now, AcuityMD is expanding its solution with sophisticated, data-driven visualizations to empower MedTech companies to connect upstream referrers to the HCPs offering their differentiated treatments. It gives a more complete view of the care journey, enabling teams to better target their innovations and improve outcomes for more patients. Supporting Overburdened Physicians According to a 2024 survey, 80% of physicians report being overworked. An aging patient population and more patients with comorbidities (i.e., obesity plus diabetes, asthma, sleep apnea, and kidney disease), combined with a serious physician shortage, makes it difficult for providers to stay current on the latest medical innovations. At the same time, MedTech companies are developing new technologies, thanks to advances in AI, robotics, and digital, at an unprecedented clip – in fact, the industry is expected to grow to $800 billion by 2030. The volume of innovation can overwhelm providers who are already feeling strained by high case volume, staffing challenges, and administrative responsibilities. They simply do not always have time to uncover the latest treatment options for their patients, nor research local doctors providing these new treatments and the outcomes patients are experiencing. MedTech companies have attempted to bridge this gap by hosting regional and local educational events with HCPs, but information blind spots remain. Comprehensive referral data is often lacking because it only captures a patient's most recent encounter. MedTech companies struggle to find all relevant HCPs who impact the patient journey, causing some patients to miss out on more effective treatments simply due to a lack of physician awareness. With AcuityMD's new Referral Pathways in Care Journeys, MedTech companies gain a comprehensive view of a provider's entire referral network to deliver better, consultative support. 'Referral Pathways takes MedTech commercialization to the next level, helping companies not only understand the clinical opportunity around an HCP, but also uncover new pathways for strategic referrals towards those HCPs,' said Megan Wilson, director of product management at AcuityMD. 'By identifying the doctors seeing the highest number of relevant patients and leveraging Referral Pathways, Care Journeys can help sales teams make smarter connections, and ultimately help ensure that patients receive the best possible care through the latest, most innovative treatments.' Uncovering Opportunities for Improved Care Referral Pathways goes beyond traditional referral data to uniquely map upstream HCPs diagnosing the specific conditions in the same location where HCPs offer a company's therapy. MedTech teams can leverage this to uncover referral connections that even the treating HCP didn't know existed. For example, Teleflex Incorporated, a global provider of medical technologies that offers solutions across therapy areas, including interventional urology, is leveraging Care Journeys to increase adoption of its minimally invasive UroLift(™) System. 'Over 14 million men in the U.S. are living with symptoms of BPH (enlarged prostate). We know their treatment journey is long, and only a small percentage (3%) elect to have a surgical intervention,' explained Anthony Parrillo, global vice president of marketing at Teleflex. 'Referral Pathways allows us to identify the healthcare providers diagnosing BPH most often in a given market, raise their awareness of the UroLift System procedure, and share with them the UroLift physician locator on our website. This new data from AcuityMD has been remarkable in helping us target more effectively and maximize our opportunity to deliver minimally invasive treatment.' Referral Pathways in AcuityMD Care Journeys is now generally available on the AcuityMD MedTech intelligence platform. Learn more this week at industry conferences: American Urological Association (AUA) Conference (April 26-29), where AcuityMD will be showcasing Care Journeys at booth #521. Device Talks Boston, where AcuityMD's Megan Wilson and Teleflex's Anthony Parrillo are presenting on Wednesday, April 30, in room 161. About AcuityMD AcuityMD is the MedTech Intelligence Platform for more than 300 MedTech companies – including six of the top 10. Commercial leaders use AcuityMD to identify target markets, surface top opportunities, and grow their business. With customers ranging from pre-commercial to enterprise, AcuityMD is committed to delivering the right insights, enabling companies to understand where and how to sell faster to accelerate the adoption of medical technology.
Associated Press
26-02-2025
- Business
- Associated Press
Profound Medical Standardizes on AcuityMD Intelligence Platform for MedTech as Foundation for Growing Organization
AcuityMD, the intelligence platform for the medical technology (MedTech) industry, has been selected by Profound Medical, a medical device company developing customizable, incision-free therapies that combine real-time magnetic resonance imaging, thermal ultrasound, and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue – specifically for prostate diseases. Profound Medical is standardizing its organization on AcuityMD's complete suite of commercial intelligence solutions to bring its breakthrough TULSA-PRO® technology to more healthcare providers nationwide. Nearly 60% of men diagnosed with low-risk prostate cancer are managed with active surveillance – a 'wait-and-see' approach – because traditional treatments often cause severe, permanent side effects such as incontinence and erectile dysfunction. Profound Medical provides patients with a better alternative for whole or partial gland ablation, whether for low-risk, intermediate-risk, or more severe disease states. Indicated for transurethral ultrasound ablation (TULSA) of prostate tissue, TULSA-PRO is the first incision-free, radiation-free treatment for prostate disease. The procedure, which is now reimbursed by Medicare with a Category 1 CPT code, can also be conveniently performed in various outpatient settings – hospitals, ambulatory surgery centers, and office-based laboratories (OBLs). AcuityMD provided Profound Medical a smart, efficient way to accelerate the delivery of TULSA-PRO to healthcare providers. Profound Medical had been using a general customer relationship management (CRM) system with spotty market data. As a fast-growing company, they needed a powerhouse system with integrated MedTech workflows that not only helped sales identify the providers that could benefit from TULSA-PRO but also incorporated reliable commercial intelligence to guide strategic decision-making. Profound Medical also wanted industry-specific functionality for territory, contract, and long-term customer engagement management. After reviewing AcuityMD's platform – including all modules Pipeline, Targeting, Markets, Territories, plus newer modules Contracts and Care Journeys, both launched in 2024 – and speaking to customer referrals, Profound Medical doubled-down on AcuityMD's entire suite. 'We are building something important and want to do it right alongside a technology provider that will partner with us as we grow,' said Tom Tamberrino, Chief Commercial Officer at Profound Medical. 'The people at AcuityMD are as driven to get TULSA-PRO into the market as we are, and their platform is proving instrumental to helping us identify which physicians are treating prostate disease and where, as well as uncovering the high-volume regions where we need to strategically hire more sales professionals.' Tamberrino added, 'We wanted a solution that was more than a one-note sales tool or generic CRM. AcuityMD provides value not just for our sales professionals but also our regional leaders, financial team, marketers, and even manufacturing groups. It's a comprehensive platform solution that delivers industry intelligence that all our teams can use for better decision-making.' AcuityMD's platform is built for the MedTech industry's unique commercialization process and combines streamlined workflows with robust data, enabling sales, marketing, and national accounts teams to build comprehensive strategies focused on their best opportunities. 'Profound Medical is solving a longstanding men's health problem by offering an innovative procedure for prostate disease that also preserves quality-of-life,' said Michael Monovoukas, CEO and co-founder of AcuityMD. 'We are proud to partner with Profound Medical to help identify their best opportunities so they can achieve their goals and bring revolutionary TULSA-PRO technology to as many patients as possible.' AcuityMD is the intelligence platform for MedTech. More than 300 MedTech companies – including six of the top 10 – use AcuityMD to identify target markets, surface top opportunities, and grow their business. With customers ranging from pre-commercial to enterprise, AcuityMD is committed to delivering the right insights so companies can understand where and how to sell faster to accelerate the adoption of medical technology. SOURCE: AcuityMD Copyright Business Wire 2025. PUB: 02/26/2025 07:05 AM/DISC: 02/26/2025 07:06 AM
